Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling

被引:0
作者
Farnaz Khodabakhsh
Parnaz Merikhian
Mohammad Reza Eisavand
Leila Farahmand
机构
[1] AJA University of Medical Sciences,Department of Genetics and Advanced Medical Technology, Medical Biotechnology Research Center, Faculty of Medicine
[2] Motamed Cancer Institute,Recombinant Proteins Department, Breast Cancer Research Center
[3] ACECR,undefined
来源
Cancer Cell International | / 21卷
关键词
Angiogenesis; VEGF; VEGFR; MUC1; Cancer; Targeted therapy;
D O I
暂无
中图分类号
学科分类号
摘要
VEGF and its receptor family (VEGFR) members have unique signaling transduction system that play significant roles in most pathological processes, such as angiogenesis in tumor growth and metastasis. VEGF-VEGFR complex is a highly specific mitogen for endothelial cells and any de-regulation of the angiogenic balance implicates directly in endothelial cell proliferation and migration. Moreover, it has been shown that overexpressing Mucin 1 (MUC1) on the surface of many tumor cells resulting in upregulation of numerous signaling transduction cascades, such as growth and survival signaling pathways related to RTKs, loss of cell-cell and cell-matrix adhesion, and EMT. It promotes gene transcription of pro-angiogenic proteins such as HIF-1α during periods of oxygen scarcity (hypoxia) to enhance tumor growth and angiogenesis stimulation. In contrast, the cytoplasmic domain of MUC1 (MUC1-C) inhibits apoptosis, which in turn, impresses upon cell fate. Besides, it has been established that reduction in VEGF expression level correlated with silencing MUC1-C level indicating the anti-angiogenic effect of MUC1 downregulation. This review enumerates the role of MUC1-C oncoprotein and VEGF in angiogenesis and metastasis and describes several signaling pathways by which MUC1-C would mediate the pro-angiogenic activities of cancer cells.
引用
收藏
相关论文
共 132 条
[1]  
Lyssiotis CA(2017)Metabolic interactions in the tumor microenvironment Trends Cell Biol 27 863-875
[2]  
Kimmelman AC(2011)Basic and therapeutic aspects of angiogenesis Cell 146 873-887
[3]  
Potente M(2013)The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy Int J Clin Exp Med 6 239-5663
[4]  
Gerhardt H(2017)Role of tumor microenvironment in tumorigenesis J Cancer 8 761-865
[5]  
Carmeliet P(2019)Challenges facing antiangiogenesis therapy: the significant role of hypoxia-inducible factor and MET in development of resistance to anti‐vascular endothelial growth factor‐targeted therapies J Cell Physiol 234 5655-1105
[6]  
Aldebasi YH(2006)Angiogenesis in cancer Vasc Health Risk Manag 2 213-75
[7]  
Wang M(2017)The role of angiogenesis in cancer treatment Biomedicines 5 34-147
[8]  
Mahdi A(2014)Vascular endothelial growth factor from embryonic status to cardiovascular pathology Rep Biochem Mol Biol 2 59-1414
[9]  
Nishida N(2001)The splice variants of vascular endothelial growth factor (VEGF) and their receptors J Cell Sci 114 853-478
[10]  
Rajabi M(2011)Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies Genes Cancer 2 1097-2012